Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Thomas J Gardner, Cynthia Bolovan-Fritts, Melissa W Teng, Veronika Redmann, Thomas A Kraus, Rhoda Sperling, Thomas Moran, William Britt, Leor S Weinberger, Domenico Tortorella
Author Information
  1. Thomas J Gardner: Mount Sinai School of Medicine, Department of Microbiology, New York, NY, USA.

Abstract

Infection by human cytomegalovirus (CMV) elicits a strong humoral immune response and robust anti-CMV antibody production. Diagnosis of virus infection can be carried out by using a variety of serological assays; however, quantification of serum antibodies against CMV may not present an accurate measure of a patient's ability to control a virus infection. CMV strains that express green fluorescent protein (GFP) fusion proteins can be used as screening tools for evaluating characteristics of CMV infection in vitro. In this study, we employed a CMV virus strain, AD169, that ectopically expresses a yellow fluorescent protein (YFP) fused to the immediate-early 2 (IE2) protein product (AD169IE2-YFP) to quantify a CMV infection in human cells. We created a high-throughput cell-based assay that requires minimal amounts of material and provides a platform for rapid analysis of the initial phase of virus infection, including virus attachment, fusion, and immediate-early viral gene expression. The AD169IE2-YFP cell infection system was utilized to develop a neutralization assay with a monoclonal antibody against the viral surface glycoprotein gH. The high-throughput assay was extended to measure the neutralization capacity of serum from CMV-positive subjects. These findings describe a sensitive and specific assay for the quantification of a key immunological response that plays a role in limiting CMV dissemination and transmission. Collectively, we have demonstrated that a robust high-throughput infection assay can analyze the early steps of the CMV life cycle and quantify the potency of biological reagents to attenuate a virus infection.

References

  1. J Infect Dis. 1998 Nov;178(5):1233-43 [PMID: 9780241]
  2. J Virol. 1998 Sep;72(9):7563-8 [PMID: 9696854]
  3. Nat Methods. 2009 Aug;6(8):577-9 [PMID: 19578384]
  4. Lancet. 1987 Oct 31;2(8566):996-9 [PMID: 2889962]
  5. Prenat Diagn. 2004 Nov;24(11):861-3 [PMID: 15565653]
  6. Blood. 2007 Aug 1;110(3):937-45 [PMID: 17440050]
  7. J Clin Immunol. 2012 Apr;32(2):300-11 [PMID: 22198680]
  8. DNA Seq. 1991;2(1):1-12 [PMID: 1666311]
  9. Clin Diagn Lab Immunol. 1997 Jul;4(4):469-73 [PMID: 9220166]
  10. J Virol. 2001 Feb;75(4):1870-8 [PMID: 11160686]
  11. J Virol. 1991 Jul;65(7):3839-52 [PMID: 1645794]
  12. Virology. 1988 Feb;162(2):478-82 [PMID: 2829429]
  13. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12396-401 [PMID: 14519856]
  14. J Virol. 1972 Oct;10(4):766-75 [PMID: 4117347]
  15. J Infect Dis. 2001 Nov 15;184(10):1252-61 [PMID: 11679913]
  16. Pediatr Infect Dis J. 1995 Jan;14(1):34-40 [PMID: 7715987]
  17. J Virol. 2006 Jan;80(2):710-22 [PMID: 16378974]
  18. J Med Virol. 2000 Mar;60(3):324-30 [PMID: 10630965]
  19. Transplant Proc. 1993 Feb;25(1 Pt 2):1441-3 [PMID: 8382875]
  20. J Med Virol. 1980;6(2):119-27 [PMID: 6264020]
  21. J Virol. 1997 Feb;71(2):1246-55 [PMID: 8995648]
  22. Cell. 2012 Dec 21;151(7):1569-80 [PMID: 23260143]
  23. Expert Rev Vaccines. 2010 Nov;9(11):1303-14 [PMID: 21087108]
  24. J Virol. 2008 Oct;82(19):9525-36 [PMID: 18653451]
  25. J Virol. 2005 Jul;79(13):8361-73 [PMID: 15956581]
  26. J Virol. 1993 Jan;67(1):489-96 [PMID: 7677958]
  27. J Virol. 2000 Jul;74(13):6132-46 [PMID: 10846097]
  28. J Virol. 1990 Mar;64(3):1079-85 [PMID: 2154594]
  29. J Virol Methods. 2008 Jul;151(1):66-73 [PMID: 18490063]
  30. J Infect Dis. 1997 Apr;175(4):944-6 [PMID: 9086155]
  31. Viral Immunol. 2000;13(3):329-41 [PMID: 11016597]
  32. J Virol. 1976 Jul;19(1):243-54 [PMID: 181595]
  33. Nature. 2007 May 17;447(7142):326-9 [PMID: 17507983]
  34. J Virol. 2002 Jan;76(2):928-32 [PMID: 11752183]
  35. Clin Transplant. 1997 Oct;11(5 Pt 1):432-7 [PMID: 9361936]
  36. J Virol. 2002 Mar;76(5):2316-28 [PMID: 11836410]
  37. J Virol. 2006 Oct;80(20):9998-10009 [PMID: 17005678]
  38. N Engl J Med. 1992 Mar 5;326(10):663-7 [PMID: 1310525]
  39. Cell Host Microbe. 2008 Apr 17;3(4):253-62 [PMID: 18407068]
  40. J Virol. 2005 Aug;79(16):10330-8 [PMID: 16051825]
  41. J Intern Med. 2006 Mar;259(3):219-46 [PMID: 16476101]
  42. PLoS One. 2010 Feb 11;5(2):e9174 [PMID: 20161802]
  43. Nucleic Acids Res. 2005 Feb 24;33(4):e36 [PMID: 15731329]
  44. J Immunol. 1986 Oct 1;137(7):2299-306 [PMID: 3760563]
  45. Vaccine. 2011 Mar 24;29(15):2705-11 [PMID: 21310190]
  46. J Virol. 2004 Sep;78(18):10023-33 [PMID: 15331735]
  47. Virology. 1975 Aug;66(2):464-73 [PMID: 168685]
  48. Virology. 1983 Oct 15;130(1):118-33 [PMID: 6314643]
  49. Mol Immunol. 2012 Jun;51(2):245-53 [PMID: 22497807]
  50. Antiviral Res. 2011 Mar;89(3):246-56 [PMID: 21277329]
  51. J Virol. 2004 Feb;78(4):1817-30 [PMID: 14747546]
  52. J Gen Virol. 2008 Apr;89(Pt 4):853-865 [PMID: 18343825]
  53. Clin Vaccine Immunol. 2011 Sep;18(9):1536-42 [PMID: 21795465]
  54. J Virol. 1989 Mar;63(3):1435-40 [PMID: 2536844]
  55. J Virol. 1997 Jun;71(6):4599-613 [PMID: 9151854]
  56. Immunol Res. 2012 Dec;54(1-3):140-51 [PMID: 22454101]
  57. J Virol. 2004 Jul;78(14):7803-12 [PMID: 15220454]
  58. Virology. 1992 Nov;191(1):387-95 [PMID: 1329327]
  59. J Virol. 1999 Feb;73(2):878-86 [PMID: 9882288]
  60. Rev Med Virol. 2007 Jul-Aug;17(4):253-76 [PMID: 17579921]
  61. Rev Infect Dis. 1990 Sep-Oct;12 Suppl 7:S745-53 [PMID: 2173104]
  62. Antimicrob Agents Chemother. 2008 Jul;52(7):2420-7 [PMID: 18458124]
  63. J Virol. 2000 Aug;74(15):7108-18 [PMID: 10888651]

Grants

  1. T32 AI007647/NIAID NIH HHS
  2. R56 DC015980/NIDCD NIH HHS
  3. R01 AI060905/NIAID NIH HHS
  4. R03 DA035190/NIDA NIH HHS
  5. K25 GM083395/NIGMS NIH HHS
  6. P30 AI027763/NIAID NIH HHS
  7. AI060905/NIAID NIH HHS
  8. GM083395/NIGMS NIH HHS
  9. T32-AI07647/NIAID NIH HHS

MeSH Term

Antibodies, Neutralizing
Antibodies, Viral
Bacterial Proteins
Cytomegalovirus
Cytomegalovirus Infections
Female
Genes, Reporter
High-Throughput Screening Assays
Humans
Luminescent Proteins
Neutralization Tests
Pregnancy
Sensitivity and Specificity
Staining and Labeling

Chemicals

Antibodies, Neutralizing
Antibodies, Viral
Bacterial Proteins
Luminescent Proteins
yellow fluorescent protein, Bacteria

Word Cloud

Created with Highcharts 10.0.0CMVinfectionvirusassayhigh-throughputcanmeasureproteinneutralizationhumanresponserobustantibodyquantificationserumantibodiesfluorescentfusionimmediate-earlyAD169IE2-YFPquantifyviralInfectioncytomegaloviruselicitsstronghumoralimmuneanti-CMVproductionDiagnosiscarriedusingvarietyserologicalassayshowevermaypresentaccuratepatient'sabilitycontrolstrainsexpressgreenGFPproteinsusedscreeningtoolsevaluatingcharacteristicsvitrostudyemployedstrainAD169ectopicallyexpressesyellowYFPfused2IE2productcellscreatedcell-basedrequiresminimalamountsmaterialprovidesplatformrapidanalysisinitialphaseincludingattachmentgeneexpressioncellsystemutilizeddevelopmonoclonalsurfaceglycoproteingHextendedcapacityCMV-positivesubjectsfindingsdescribesensitivespecifickeyimmunologicalplaysrolelimitingdisseminationtransmissionCollectivelydemonstratedanalyzeearlystepslifecyclepotencybiologicalreagentsattenuateDevelopmentcapabilityanti-cytomegalovirus

Similar Articles

Cited By